ArticleProceedings of the National Academy of Sciences of the United States of America2007
Predicting response to breast cancer neoadjuvant chemotherapy using diffuse optical spectroscopy.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 154 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
154 citing papers in PubMed, 1 synthesis or guideline pooled it, 292 citations in OpenAlex.
- Diffuse optical spectroscopy for monitoring the responses of patients with breast cancer to neoadjuvant chemotherapy: A meta-analysis.Medicine · 2018Pooled it
- Prediction of neoadjuvant chemotherapy response using diffuse optical spectroscopy in breast cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2018Trial
- Noninvasive optical spectroscopy for identification of non-melanoma skin cancer: Pilot study.Lasers in surgery and medicine · 2018Trial
- Early prediction of therapy responses and outcomes in breast cancer patients using quantitative ultrasound spectral texture.Oncotarget · 2014Trial
- Trial
- Noninvasive monitoring of breast cancer during neoadjuvant chemotherapy using optical tomography with ultrasound localization.Neoplasia (New York, N.Y.) · 2008Trial
- Serum biomarker profiles and response to neoadjuvant chemotherapy for locally advanced breast cancer.Breast cancer research : BCR · 2008Trial
- Quantitative Ultrasound Radiomics for Predicting and Monitoring Neoadjuvant Chemotherapy Response in Breast Cancer: A Systematic Review.Diagnostics (Basel, Switzerland) · 2026Review
- Review of shortwave infrared imaging and spectroscopy in tissue [Invited].Biomedical optics express · 2025Review
- Frequency domain broadband short-wave infrared spectroscopy for measurement of tissue optical properties from 685 to 1300 nm.Journal of biomedical optics · 2025Article
- Broad-Bandwidth Frequency-Domain Near-Infrared Spectroscopy System on a Chip.IEEE sensors journal · 2025Article
- Prediction of Chemotherapy Response in Locally Advanced Breast Cancer Patients at Pre-Treatment Using CT Textural Features and Machine Learning: Comparison of Feature Selection Methods.Tomography (Ann Arbor, Mich.) · 2025Article
- Establishing the feasibility and reliability of broadband absorption spectroscopy for measuring cerebral water content in adults.Biomedical optics express · 2025Article
- Advancing Near-Infrared Probes for Enhanced Breast Cancer Assessment.Sensors (Basel, Switzerland) · 2025Article
- Solid breast tumors phantom emulating oxy and deoxyhemoglobin concentrations for near infrared imaging.PloS one · 2025Article
- Functional hemodynamic imaging markers for the prediction of pathological outcomes in breast cancer patients treated with neoadjuvant chemotherapy.Journal of biomedical optics · 2024Article
- Noninvasive hemoglobin quantification across different cohorts using a wearable diffuse reflectance spectroscopy system.Biomedical optics express · 2024Article
- In Vivo Raman Spectroscopy Reveals Biochemical Composition of the Esophageal Tissue in Pediatric Eosinophilic Esophagitis.Clinical and translational gastroenterology · 2024Article
- Differentiating Primary and Recurrent Lesions in Patients with a History of Breast Cancer: A Comprehensive Review.Galen medical journal · 2024Article
- Apriori prediction of chemotherapy response in locally advanced breast cancer patients using CT imaging and deep learning: transformer versus transfer learning.Frontiers in oncology · 2024Article
94 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Diffuse optical spectroscopy (DOS) and imaging are emerging diagnostic techniques that quantitatively measure the concentration of deoxy-hemoglobin (ctHHb), oxy-hemoglobin (ctO(2)Hb), water (ctH(2)O), and lipid in cm-thick tissues. In early-stage clinical studies, diffuse optical imaging and DOS have been used to characterize breast tumor biochemical composition and monitor therapeutic response in stage II/III neoadjuvant chemotherapy patients. We investigated whether DOS measurements obtained before and 1 week into a 3-month adriamycin/cytoxan neoadjuvant chemotherapy regimen can predict final, postsurgical pathological response. Baseline DOS measurements of 11 patients before therapy revealed significant increases in tumor ctHHb, ctO(2)Hb, ctH(2)O, and spectral scattering slope, and decreases in bulk lipids, relative to normal breast tissue. Tumor concentrations of ctHHb, ctO(2)Hb, and ctH(2)O dropped 27 +/- 15%, 33 +/- 7%, and 11 +/- 15%, respectively, within 1 week (6.5 +/- 1.4 days) of the first treatment for pathology-confirmed responders (n = 6), whereas nonresponders (n = 5) and normal side controls showed no significant changes in these parameters. The best single predictor of therapeutic response 1 week posttreatment was ctHHb (83% sensitivity, 100% specificity), while discrimination analysis based on combined ctHHb and ctH(2)O changes classified responders vs. nonresponders with 100% sensitivity and specificity. In addition, the pretreatment tumor-to-normal ctO(2)Hb ratio was significantly higher in responders (2.82 +/- 0.44) vs. nonresponders (1.82 +/- 0.49). These results highlight DOS sensitivity to tumor cellular metabolism and biochemical composition and demonstrate its potential for predicting and monitoring an individual's response to treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.